Discontinuation of Risperidone and Reversibility of Weight Gain in Children with Disruptive Behavior Disorders
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Although atypical antipsychotics generally have a good side effect profile and are clinically very effective, weight gain and associated problems accompany their use. The authors followed up 14 subjects who were in studies of risperidone for management of disruptive behavior disorders. The subjects exited after a mean exposure of 8.9 months because of excessive weight gain, or excessive appetite, or insufficient clinical response. Weight was monitored for the full cohort before risperidone treatment, at termination, and (for various subgroups) at 3, 9-12, and 24 months after termination. Analysis of standardized weight scores in relation to standardized BMI scores suggested marked similarity between them at all time points. Comparison of standardized weights at time of drug termination with 3, 9-12, and 24 months after termination indicated that weight gain during risperidone treatment is reversible (i.e., significantly less weight after risperidone was discontinued) at all time points after termination. Furthermore, standardized weight at 12 and 24 months after discontinuation of risperidone was not distinguishable from standardized weight before risperidone. The prospect of reversibility may provide some comfort for clinicians and parents alike, but far more data are needed before an assumption can be made that this is the case for all children. The authors provide several recommendations for clinicians and researchers working with atypical antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Self-citationAman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1337 · Cited by 475
Self-citationEffects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs
SNYDER, R., TURGAY, A., AMAN, M., BINDER, C., FISMAN, S., & CARROLL, A. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00002 · Cited by 335
Self-citation
Cited by
De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 362
Anagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., Brian, J., Arnold, L. E., Capano, L., Hellings, J. A., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1232 · Cited by 123
Self-citationThe Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Upadhyay, N., Patel, A., Chan, W., Aparasu, R. R., Ochoa-Perez, M., Sherer, J. T., Sanyal, S., & Chen, H. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.05.005 · Cited by 11
Hulvershorn, L., Parkhurst, S., Jones, S., Dauss, K., & Adams, C. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0040 · Cited by 6
“We hypothesized that (1) youth who experienced AAP discontinuation would show improved metabolic vital signs and electro-cardiogram (EKG) metrics (Lindsay et al. 2004; Correll et al. 2009; Moreno et al. 2010; Calarge et al. 2014), (2) some youth would experience a worsening of…”
Metadata
- Authors
- Lindsay, R. L., Leone, S., & Aman, M. G.
- Venue
- Clinical Pediatrics
- Publisher
- SAGE Publications
- Published
- 2004-06
- Volume
- 43
- Issue
- 5
- Pages
- 437-444
- ISSN
- 0009-9228 (ISSN-L)
- 1938-2707
- OpenAlex
- W2119604995
- Cited by
- 27
- References
- 3
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation of Risperidone and Reversibility of Weight Gain in Children with Disruptive Behavior Disorders. https://app.cochat.ai/papers/10.1177/000992280404300504
- The paper
- Lindsay, R. L., Leone, S., & Aman, M. G. (2004). Discontinuation of Risperidone and Reversibility of Weight Gain in Children with Disruptive Behavior Disorders. Clinical Pediatrics. https://doi.org/10.1177/000992280404300504
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.